Boston, MA 10/21/2013 (wallstreetpr) – Separate civil lawsuits that were filed against Pfizer Inc. (NYSE:PFE) in the McDowell County civil court in West Virginia have now been moved to the federal docket in the US District Court for the Southern District of West Virginia and will now be handled there. There were multiple plaintiffs involved in some of the original civil cases but the docket in the federal docket will have the cases listed individually.
According to the complaint filed on Sept. 4, the civil lawsuit is being brought against Pfizer seeking damages for the “unsafe prescription drug Lipitor.” The complaint also goes on to state that “Lipitor is associated with, and cases, an increased risk of type 2 diabetes and/or blood glucose levels diagnostic for type 2 diabetes.
“Because of this increased risk of type 2 diabetes, Lipitor is also associated with, and causes an increased risk of heart disease, blindness, neuropathy, kidney disease and other dangerous conditions.” Allegations by the plaintiffs in the case are that Pfizer never advised the public of the correlation between taking the drug Lipitor and changes that occur in blood sugar levels. Individual problems encountered by each plaintiff are then listed on the complaint.
Pfizer has responded to the civil cases by pointing out that the drug Lipitor received FDA approval after going through the standard rigorous clinical trials and the labeling for the drug was also approved for use by the FDA. The company is refuting all claims being made that their product is responsible for any of the injury being claimed and they have asked the courts to completely dismiss the complaint. Pfizer also stated in its response to the allegations that though Lipitor will have side effects and risks involved with its usage, these pale in significance to the benefits offered by its use.
The complainants in the case are seeking monetary compensation to cover purchase costs, legal fees, restitution as well as other punitive damages.